GLP1R and metabolic dysfunction-associated steatohepatitis: The recent approval of resmetirom and the clinical success of GLP‐1 receptor agonists have heralded a new era in MASH therapy, yet a convergent understanding of the complex mechanisms of these diverse agents is lacking.